What is the recommended intravenous dosing regimen for tigecycline, including loading dose, maintenance dose, adjustments for severe hepatic impairment (Child‑Pugh class C) and intermittent hemodialysis, and typical treatment duration?

Tigecycline Intravenous Dosing

The standard dosing regimen for tigecycline is a 100 mg IV loading dose followed by 50 mg IV every 12 hours, with dose reduction to 25 mg every 12 hours in severe hepatic impairment (Child-Pugh C), and no adjustment needed for renal impairment or hemodialysis. 1

Standard Adult Dosing

• Loading dose: 100 mg IV infused over 30-60 minutes
• Maintenance dose: 50 mg IV every 12 hours, infused over 30-60 minutes
• Treatment duration:
  • Complicated skin/skin structure infections: 5-14 days
  • Complicated intra-abdominal infections: 5-14 days 2
  • Community-acquired pneumonia: 7-14 days 1

Hepatic Impairment Adjustments

Dose adjustment is required only for severe hepatic impairment:

• Child-Pugh A (mild): No adjustment needed - use standard 50 mg every 12 hours 1
• Child-Pugh B (moderate): No adjustment needed - use standard 50 mg every 12 hours 1
• Child-Pugh C (severe): 100 mg loading dose, then reduce maintenance to 25 mg every 12 hours 1

This 50% dose reduction in Child-Pugh C patients is supported by pharmacokinetic data showing tigecycline clearance decreases to approximately 13.5 L/h (compared to 29.8 L/h in healthy subjects), representing a roughly 55% reduction in clearance 3. Recent population pharmacokinetic studies confirm that MELD score significantly influences tigecycline clearance, with elimination progressively impaired as MELD scores increase 4.

Renal Impairment and Hemodialysis

No dose adjustment is required for any degree of renal impairment or hemodialysis 5. Key evidence:

• Renal clearance represents only ~20% of total systemic clearance
• In severe renal impairment (CrCl <30 mL/min), tigecycline clearance decreases by only ~20% and AUC increases by ~30%
• Tigecycline is not efficiently removed by dialysis
• Can be administered without regard to timing of hemodialysis 5

High-Dose Considerations for Specific Infections

While not FDA-approved, higher dosing regimens (200 mg loading, then 100 mg every 12 hours) have been used for serious infections, particularly:

• Hospital-acquired/ventilator-associated pneumonia (though tigecycline is NOT indicated for HAP/VAP due to increased mortality) 6
• Carbapenem-resistant Enterobacterales (CRE) bloodstream infections when used in combination therapy 6

Critical caveat: The FDA label explicitly warns against using tigecycline for HAP/VAP due to greater mortality and decreased efficacy observed in comparative trials 1. Guidelines recommend against tigecycline monotherapy for CRAB pneumonia 2.

Pediatric Dosing (Not Recommended)

Use in patients <18 years is NOT recommended due to increased mortality in adult trials and effects on tooth development in children <8 years 1. If absolutely no alternatives exist:

• Ages 8-11 years: 1.2 mg/kg every 12 hours IV (maximum 50 mg per dose) 2
• Ages 12-17 years: 50 mg every 12 hours IV 2

Important Clinical Pitfalls

1. Do not use for complicated UTI: Tigecycline shows inferior outcomes compared to aminoglycosides for CRE-related urinary tract infections 6

2. Avoid monotherapy for serious infections: For CRE bloodstream infections and CRAB pneumonia, combination therapy is preferred over tigecycline monotherapy 2

3. Monitor in severe hepatic impairment: Patients with Child-Pugh C require close monitoring for treatment response when using the reduced 25 mg dose 1

4. Common adverse effects: Nausea (28.5%), vomiting (19.4%), and diarrhea (11.6%) are frequent, particularly with standard dosing 7